Скачать с ютуб The Future of ATMPs in Europe в хорошем качестве

The Future of ATMPs in Europe

The Alliance for Regenerative Medicine (ARM) and MEP Dr. Stelios Kympouropoulos held an event on November 29 at the European Parliament to highlight concerning trends for advanced therapy medicinal product (ATMP) developers, clinical trials, and investment in the European Union (EU). At the event, ARM and many speakers emphasized the EU can reverse its declining competitiveness and ensure patient access to transformative treatments if it modernizes its policy and regulatory framework to reflect the distinct promise of cell and gene therapies as the future of medicine. To learn more, read our call to action: http://alliancerm.org/wp-content/uplo... Event speakers featured: Dr. Stelios Kympouropoulos, MEP, European People's Party Tim Hunt, Chief Executive Officer, Alliance for Regenerative Medicine Emily Whitehead & Tom Whitehead, Emily Whitehead Foundation Sylvain Giraud, Head of Unit ‘Medical Products: Quality, Safety, Innovation’, DG Sante, European Commission Patrick Celis, Scientific Administrator, Committee for Advanced Therapies, European Medicines Agency Lucy Ellerker, Patient Advocate Simone Boselli, Director of Public Affairs, EURORDIS Rare Disease Europe Susana Solís Perez, MEP Chris Vann, Chief Operating Officer at Autolus, and Member of the Alliance for Regenerative Medicine’s Board Dr Miguel Forte, President-Elect of the International Society for Cell & Gene Therapy, and Member of the Alliance for Regenerative Medicine’s Board